Kombi-Therapie für RNA-Virus-Erkrankungen mit Pyrimidin-Synthesehemmern und Nukleotidanaloga
Die COVID-19-Pandemie hat sich als die schwerste Gesundheitskrise der Neuzeit erwiesen. Zur Bekämpfung von RNA-Virusinfektionen wie SARS, Influenza, Hepatitis C, HIV und sogar Ebola wurde ein neuer kombinierter therapeutischer Ansatz aus Pyrimidin-Analoga und Pyrimidin-Biosynthese-Hemmern entwickelt.
Combination therapy for RNA virus diseases with pyrimidine synthesis inhibitors and nucleotide analogues
The COVID-19 pandemic has emerged as the most serious health crisis in modern times. To combat RNA viral infections like SARS, Influenza, Hepatitis C, HIV or even Ebola a new combination therapeutic approach of pyrimidine analogues and pyrimidine biosynthesis inhibitors has been discovered.
Pet food mouldings for dogs and cats with excellent taste and low caloric value
The present invention relates to a method for producing dry pet food articles from puffed corn in all kinds of shapes and forms with good taste and low caloric value.
New therapeutic target against bacterial or viral infections
Targeting key proteins in viral or bacterial pathogens is an appealing way to combat infectious diseases. A new protein domain has been discovered as a therapeutic target.
Reducing the mortality rate of patients after Aortic-Valve Implantation by Anti-Fibrotic Treatment
A subpopulation of patients with a very high rist to die in only one year after an aortic valve implantation (AVI) was identified. A novel treatment may save lives by analysing the level of fibrosis in the heart tissue.
GMP-compatible Methods for producing tissue-engineered human heart muscle from stem cells
Heart tissue engineering using stem cells is a recently developed technique to construct a three dimensional cell structure from cardiomyocytes or directly from progenitor cells. Scientists at the University of Göttingen developed two new and fully defined methods for serum-free production of engineered human heart muscles.
Improved marker vaccine against classical swine fever
Scientists at the University of Veterinary Medicine Hanover developed a new marker vaccine for classical swine fever based on chimeric pestiviruses with improved DIVA (Differentiating Infected from Vaccinated Animals) properties. The used marker Erns is a chimeric sequence of two different and remotely related pestiviruses.
EYA1 — Biomarker and therapeutic target for kidney fibrosis
The EYA1 splicing was found to be linked with the progression of fibrosis. Patients expressing predominantly EYA1-A ("bad" variant) end up in the end stage renal disease earlier and suffer from a higher mortality. A shift of splicing towards EYA1-C ("good" variant) effectively attenuates fibrosis in vivo (mouse model).
Therapy of Alzheimer's Disease with an antibody against oligomeric pyro-Glu-Abeta peptides
Scientists at the University of Göttingen developed a novel, proprietary antibody for the therapy and/or diagnosis of Alzheimer's Disease (AD) through the targeting of specifically pyro-Glu-Amyloid beta peptides.
Animal model for Gastrointestinal Stromal Tumor (GIST)
Gastrointestinal stromal tumor (GIST) is one of the most common mesenchymal tumors of the gastrointestinal tract. GISTs occur in 10-20 per one million people. Thus, GIST has been named as an orphan drug disease. Scientists at the University of Göttingen developed a new animal drug screening model for GIST.
New transgenic mouse model for sporadic Alzheimer's Disease. It does not have any mutation and it shows neurological deficits by transgenic over-expressing a major form of amyloid beta peptides (N-truncated Abeta 4-42) found in the brain of AD patients.
Arthritic diseases are conditions involving damages to the joints and/or cartilage. A primary form of arthritis is for example rheumatoid arthritis, which affects over 21 million people worldwide. Scientists at the University of Göttingen have developed a new animal drug screening model for arthritic diseases.
Scientists at the University of Göttingen developed new highly potent drugs (with an IC50 in the pico-molar range) as well as a selective tumor therapy through their prodrugs. Selectivity is achieved by antibody tumor targeting. The highly soluble prodrugs are activated into the cytotoxic drugs only at tumor site.